186 related articles for article (PubMed ID: 29913470)
1. Inotuzumab ozogamicin (Besponsa)--an antibody-drug conjugate for ALL.
Med Lett Drugs Ther; 2018 May; 60(1547):e90-e91. PubMed ID: 29913470
[No Abstract] [Full Text] [Related]
2. Inotuzumab Ozogamicin: First Global Approval.
Lamb YN
Drugs; 2017 Sep; 77(14):1603-1610. PubMed ID: 28819740
[TBL] [Abstract][Full Text] [Related]
3. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin.
Kantarjian H; Jabbour E
Am Soc Clin Oncol Educ Book; 2018 May; 38():574-578. PubMed ID: 30231308
[TBL] [Abstract][Full Text] [Related]
4. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
Choudhry A; O'Brien SM
Drugs Today (Barc); 2017 Dec; 53(12):653-665. PubMed ID: 29517084
[TBL] [Abstract][Full Text] [Related]
5. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
6. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.
Thota S; Advani A
Eur J Haematol; 2017 May; 98(5):425-434. PubMed ID: 28152223
[TBL] [Abstract][Full Text] [Related]
7. Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia.
Bertamini L; Nanni J; Marconi G; Abbenante M; Robustelli V; Bacci F; Matti A; Paolini S; Sartor C; Monaco SL; Fontana MC; De Polo S; Cavo M; Curti A; Martinelli G; Papayannidis C
BMC Cancer; 2018 Nov; 18(1):1117. PubMed ID: 30442119
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
Shor B; Gerber HP; Sapra P
Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
[TBL] [Abstract][Full Text] [Related]
9. In brief: Brentuximab vedotin (Adcetris) for classical hodgkin's lymphoma.
Med Lett Drugs Ther; 2018 Nov; 60(1559):e185. PubMed ID: 30681659
[No Abstract] [Full Text] [Related]
10. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.
Wynne J; Wright D; Stock W
Blood Adv; 2019 Jan; 3(1):96-104. PubMed ID: 30622147
[TBL] [Abstract][Full Text] [Related]
11. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
Ricart AD
Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
[TBL] [Abstract][Full Text] [Related]
12. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
Dahl J; Marx K; Jabbour E
Expert Rev Hematol; 2016; 9(4):329-34. PubMed ID: 26783163
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.
Ogura M; Hatake K; Ando K; Tobinai K; Tokushige K; Ono C; Ishibashi T; Vandendries E
Cancer Sci; 2012 May; 103(5):933-8. PubMed ID: 22335424
[TBL] [Abstract][Full Text] [Related]
14. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS
Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684
[TBL] [Abstract][Full Text] [Related]
15. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.
Paul S; Rausch CR; Kantarjian H; Jabbour EJ
Future Oncol; 2017 Oct; 13(25):2233-2242. PubMed ID: 28776425
[TBL] [Abstract][Full Text] [Related]
16. Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia.
Thomas X
Expert Opin Investig Drugs; 2012 Jun; 21(6):871-8. PubMed ID: 22500551
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance.
Paul MR; Wong V; Aristizabal P; Kuo DJ
J Pediatr Hematol Oncol; 2019 Nov; 41(8):e546-e549. PubMed ID: 30807395
[TBL] [Abstract][Full Text] [Related]
18. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
[TBL] [Abstract][Full Text] [Related]
19. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.
Betts AM; Haddish-Berhane N; Tolsma J; Jasper P; King LE; Sun Y; Chakrapani S; Shor B; Boni J; Johnson TR
AAPS J; 2016 Sep; 18(5):1101-1116. PubMed ID: 27198897
[TBL] [Abstract][Full Text] [Related]
20. Loss of CD22 expression and expansion of a CD22
Reinert J; Beitzen-Heineke A; Wethmar K; Stelljes M; Fiedler W; Schwartz S
Ann Hematol; 2021 Nov; 100(11):2727-2732. PubMed ID: 34331563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
